MainPercentage of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)Patient Representatives participate in advisory committee meetings to ensure patient input on important medical product review and policy questions.The Patient Representative’s role is to provide the advisory committee and FDA insight on issues, problems, and/or questions pertinent to the unique viewpoint of patients living with a specific disease.(1) This measure will no longer be tracked after April 2012.Percentcolumn01501002010FY 2010 Overall: 73%01002011FY 2011 Overall: 88%01002012FY 2012 Oct-Apr Overall: 93%SubPercentage of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)Number of FDA advisory committee meetings during the month that had a Patient Representative (1)Numbercolumn0152010FY 2010 Total: 640152011FY 2011 Total: 532012FY 2012 Oct-Apr Total: 38SubPercentage of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)Number of FDA advisory committee meetings during the month, that were identified as needing a Patient Representative, that had a Patient Representative (1)Numbercolumn0152010FY 2010 Total: 880152011FY 2011 Total: 602012FY 2012 Oct-Apr Total: 41MainTotal number of advisory committee meetings during the month (1)Numbercolumn0152010FY 2010 Total: 890152011FY 2011 Total: 782012FY 2012 Oct-Apr Total: 44http://www.fda.gov/AboutFDA/Transparency/track/ucm206211.htmFDA-TRACK OC Administrative Offices Dashboard਍††਍਍਍਍਍਍਍